Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
NCT05453396 · University of Washington · PHASE2 · terminated · last registry update 2026-06-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The trial closed early due to slow accrual.” | – | Registry record, University of Washington |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD19 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-05Phase 3 first posted: Merck Sharp & Dohme LLC, MK-1045 + Zilovertamab vedotin (NCT07917754)
- 2026-11-04Also stopped (suspended): Masonic Cancer Center, University of Minnesota, E7777 + Fludarabine (NCT04855253)
- 2026-10-21Results posted on the registry: Incyte Biosciences Japan GK, tafasitamab + lenalidomide (NCT04661007)
- 2026-10-16Results posted on the registry: Nektar Therapeutics, NKTR-255 at 1.5 µg/kg + NKTR-255 at 3.0 μg/kg (NCT05664217)
- 2026-10-16Also stopped (terminated): Nektar Therapeutics, NKTR-255 at 1.5 µg/kg + NKTR-255 at 3.0 μg/kg (NCT05664217)
- 2026-10-08Also stopped (suspended): M.D. Anderson Cancer Center, Blinatumomab (NCT07192237)
- 2026-10-01Phase 3 first posted: Amgen, Inebilizumab + Tacrolimus (NCT07851220)
- 2026-09-25Results posted on the registry: M.D. Anderson Cancer Center, Blinatumomab (NCT02458014)
- 2026-09-11Also stopped (suspended): Fred Hutchinson Cancer Center, Vevoctadekin + Lisocabtagene Maraleucel (NCT07098364)
- 2026-08-18Results posted on the registry: Kite, A Gilead Company, Fludarabine + Cyclophosphamide (NCT04880434)
- 2026-08-10Results posted on the registry: NeoImmuneTech, Efineptakin alfa + Tisagenlecleucel (NCT05075603)
- 2026-07-23Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, BLB101 for Injection + Blinatumomab for Injection (NCT07723911)
- 2026-07-22Also stopped (withdrawn): University of Pennsylvania, CD19 redirected autologous T cells (CTL019 or CTL119 cells) (NCT04419909)
- 2026-07-20Also stopped (terminated): ADC Therapeutics S.A., Loncastuximab Tesirine (NCT05660395)
- 2026-06-25Results posted on the registry: University of Washington, Acalabrutinib + Axicabtagene Ciloleucel (NCT04257578)
- 2026-06-09Results posted on the registry: University of California, Davis, Blinatumomab + Ibrutinib (NCT02997761)
- 2026-05-20Phase 3 first posted: Amgen, Inebilizumab + Placebo (NCT07598825)
- 2026-05-13Results posted on the registry: Amgen, Blinatumomab (NCT06649006)
- 2026-05-06Phase 3 first posted: Merck Sharp & Dohme LLC, MK-1045 + Blinatumomab (NCT07570173)
- 2026-04-07Also stopped (withdrawn): Memorial Sloan Kettering Cancer Center, Epcoritamab + Lenalidomide (NCT07030699)
- 2026-03-18Phase 3 first posted: Kite, A Gilead Company, KITE-753 + Axicabtagene Ciloleucel (NCT07479797)
- 2026-03-18Also stopped (withdrawn): Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, Cyclophosphamide + Doxorubicin (NCT06313996)
- 2026-03-17Phase 3 first posted: Charite University, Berlin, Germany, Inotuzumab ozogamicin (INO) + Blinatumomab (NCT07476729)
- 2026-03-10Results posted on the registry: Amgen, inebilizumab + IV Placebo (NCT04524273)
- 2026-03-10Results posted on the registry: Kite, A Gilead Company, Brexucabtagene Autoleucel + Cyclophosphamide (NCT05537766)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision